| Pharmaceutical Information |
| Drug Name |
Pegloticase |
| Drug ID |
BADD_D01698 |
| Description |
Pegloticase is a recombinant porcine-like uricase drug indicated for the treatment of severe, treatment-refractory, chronic gout. Similarly to rasburicase, pegloticase metabolises the conversion of uric acid to allantoin. This reduces the risk of precipitate formation and development of gout, since allantoin is five to ten times more soluble than uric acid. Pegloticase is a pegylated form of uricase which offers an extended half-life of ten-12 days compared to rasburicase's 8 hours. It also offers reduced immunogenicity due to the bulky PEG group. The longer haf-life allows for less frequent dosing at once every 2-4 weeks making pegloticase more convenient for chronic use. |
| Indications and Usage |
For the treatment of chronic gout in adult patients refractory to conventional therapy. |
| Marketing Status |
approved; investigational |
| ATC Code |
M04AX02 |
| DrugBank ID |
DB09208
|
| KEGG ID |
D09316
|
| MeSH ID |
C031545
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D06ZIT
|
| NDC Product Code |
75987-080 |
| UNII |
R581OT55EA
|
| Synonyms |
Pegloticase | polyethylene glycol-uricase | PEG-uricase | methoxypolyethylene glycol uricase | Krystexxa | Puricase |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
885051-90-1 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
